ArticleGenes & genomics2026
Integrated analysis identifies conserved transcription factors TCF12, E2F1, and TEAD4 with diagnostic and therapeutic value in osteoarthritis subchondral bone.
Article in Genes & genomics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundOsteoarthritis (OA) is a multifactorial joint disease involving both cartilage and subchondral bone. The molecular mechanism of subchondral bone in OA is still unclear.
objectiveThis study aimed to identify key molecular targets and transcription factors (TFs) in subchondral bone that drive OA progression, with a focus on their diagnostic and therapeutic potential.
methodsDifferentially expressed genes (DEGs) from human OA patients and rat OA models were analyzed using RNA-seq data from GEO database. Then functional enrichment analysis, including GSEA, GO and KEGG revealed high conservation. The iRegulon analysis was applied to identify common TFs. Bingo analysis linked TF target genes to OA-relevant biological functions, and single-cell RNA sequencing (sc-RNA seq) identified the primary cell types expressing these TFs. Finally, the expression of identified TFs was validated in human OA and animal OA samples using immunofluorescence (IF) and qPCR.
resultsWe identified 77 common DEGs in OA patients and rat models, including genes associated with bone development or remodeling. Functional enrichment analysis identified common biological processes, such as skeletal system development, and shared pathways, including calcium signaling, across both species. Moreover, iRegulon analysis identified three conserved TFs-Transcription Factor 12 (TCF12), E2F Transcription Factor 1 (E2F1), and TEA domain transcription factor 4 (TEAD4) in both humans and rats. Single-cell analysis revealed that TFs mainly originate from bone-related cell populations. Finally, experimental validation confirmed that TCF12 was up-regulated, while E2F1 and TEAD4 were down-regulated in human OA subchondral bone and mouse DMM model.
conclusionsThis study highlights TCF12, E2F1, and TEAD4 as key regulators of subchondral bone remodeling in OA. Their conserved expression patterns across species and strong correlation with OA progression suggest their potential as novel diagnostic markers and therapeutic targets for OA intervention.
Indexed as
Identifiers
41296172What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.